It notched convincing beats on analyst estimates with its second-quarter performance.

Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the ...

Investors anxiously waiting for Bristol Myers Squibb’s key Alzheimer’s disease psychosis readout for Cabenfy will have to ...

SAN FRANCISCO — There were theoretical contract numbers discussed and a financial divide within the preliminary stages of negotiation between Bob Myers and Joe Lacob in relation to Myers’ future. But ...

Myers Industries smashed earnings with a 47% EPS beat as margin expansion from its Focused Transformation program offset a ...